Nuvectis Pharma, Inc. Expected to Earn FY2028 Earnings of $3.90 Per Share (NASDAQ:NVCT)

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Research analysts at Roth Capital boosted their FY2028 earnings estimates for Nuvectis Pharma in a research report issued to clients and investors on Tuesday, May 7th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of $3.90 for the year, up from their prior forecast of $3.59. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.52) per share.

Nuvectis Pharma (NASDAQ:NVCT) last issued its earnings results on Tuesday, March 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01).

Separately, HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of Nuvectis Pharma in a report on Wednesday.

Nuvectis Pharma Price Performance

Nuvectis Pharma stock opened at $6.43 on Thursday. Nuvectis Pharma has a 1 year low of $5.92 and a 1 year high of $18.65. The company has a market capitalization of $118.13 million, a P/E ratio of -4.50 and a beta of 0.45. The business has a 50 day moving average of $8.17 and a 200-day moving average of $8.21.

Institutional Trading of Nuvectis Pharma

Institutional investors have recently bought and sold shares of the company. Strs Ohio grew its holdings in Nuvectis Pharma by 178.6% in the third quarter. Strs Ohio now owns 3,900 shares of the company’s stock worth $50,000 after purchasing an additional 2,500 shares during the period. Blue Zone Wealth Advisors LLC acquired a new stake in shares of Nuvectis Pharma in the 1st quarter valued at about $118,000. Edmond DE Rothschild Holding S.A. bought a new stake in Nuvectis Pharma in the 4th quarter valued at about $160,000. Finally, Baldwin Brothers LLC MA raised its stake in Nuvectis Pharma by 22.0% during the 4th quarter. Baldwin Brothers LLC MA now owns 142,040 shares of the company’s stock worth $1,185,000 after buying an additional 25,660 shares during the period. Institutional investors own 96.77% of the company’s stock.

Insider Activity

In other news, CEO Ron Bentsur bought 5,000 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was acquired at an average price of $10.29 per share, with a total value of $51,450.00. Following the transaction, the chief executive officer now owns 3,242,484 shares of the company’s stock, valued at approximately $33,365,160.36. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders own 38.85% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.